Oncotarget

Research Papers:

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells

Shuhei Suzuki _, Masashi Okada, Keita Shibuya, Manabu Seino, Atsushi Sato, Hiroyuki Takeda, Shizuka Seino, Takashi Yoshioka and Chifumi Kitanaka

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:458-470. https://doi.org/10.18632/oncotarget.2693

Metrics: PDF 2797 views  |   HTML 2626 views  |   ?  


Abstract

Shuhei Suzuki1,2,3,*, Masashi Okada1,*, Keita Shibuya1,4,5, Manabu Seino1,6, Atsushi Sato7, Hiroyuki Takeda1,2, Shizuka Seino1,4,5,8, Takashi Yoshioka2, Chifumi Kitanaka1,4,5,8

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan

2Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

3Department of Regional Cancer Network, Yamagata University School of Medicine, Yamagata 990-9585, Japan

4Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata 990-9585, Japan

5Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo 102-8471, Japan

6Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

7Department of Neurosurgery, Yamagata University School of Medicine, Yamagata 990-9585, Japan

8Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata 990-9585, Japan

*These authors contributed equally to this work

Correspondence to:

Chifumi Kitanaka, e-mail: ckitanak@med.id.yamagata-u.ac.jp

Keywords: cancer initiating cells, chemotherapy, combination therapy, c-Jun N-terminal kinase

Received: September 01, 2014     Accepted: November 03, 2014     Published: November 19, 2014

ABSTRACT

Chemoresistance associated with cancer stem cells (CSCs), which is now being held responsible for the pervasive therapy resistance of pancreatic cancer, poses a major challenge to the successful management of this devastating malignancy. However, the molecular mechanism underlying the marked chemoresistance of pancreatic CSCs remains largely unknown. Here we show that JNK, which is upregulated in pancreatic CSCs and contributes to their maintenance, is critically involved in the resistance of pancreatic CSCs to 5-fluorouracil (5-FU) and gemcitabine (GEM). We found that JNK inhibition effectively sensitizes otherwise chemoresistant pancreatic CSCs to 5-FU and GEM. Significantly, JNK inhibition promoted 5-FU- and GEM-induced increase in intracellular reactive oxygen species (ROS), and scavenging intracellular ROS by use of N-acetylcysteine impaired JNK inhibition-mediated promotion of the cytotoxicity of 5-FU and GEM. Our findings thus suggest that JNK may contribute to the chemoresistance of pancreatic CSCs through prevention of chemotherapeutic agents-induced increase in intracellular ROS. Our findings also suggest that JNK inhibition combined with 5-FU- and/or GEM-based regimens may be a rational therapeutic approach to effectively eliminate pancreatic CSCs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2693